In percentage that means 16.7 percent of the overall Cuba population has been vaccinated since immunization began in mid May amidst a hard economic situation worsened by the US blockade.

Official data indicate that by July 11, seven million 507,406 doses of Cuban vaccine candidates Abdala and Soberana 02 had been administered.

In addition to the people vaccinated with the three doses, another three million 47 thousand 144 have received at least one dose of one of the products and two million 565 thousand 754 have already received the second jab.

Cuba has developed three Covid-19 vaccines whose efficacy exceeds the limit set by the World Health Organization (50 percent) to be declared vaccines and one of them, Abdala, has already been authorized for emergency use on the island.

Abdala, developed by the Center of Genetic Engineering and Biotechnology (CIGB, in Spanish), the first vaccine in Latin America, showed 92.28 percent efficacy in its three-injection schedule.

In addition, Finlay Vaccine Institute’s Soberana 02, with two injections, proved 65.6 percent efficacy, and with a third shot of Soberana Plus the immunization rises to 91.2 percent.

The three Cuban proposals mentioned above are joined by Mambisa, also from CIGB and the only one to be applied nasally, which has already received authorization to begin Phase II clinical trials; and Soberana 01.

mh/mem/cdg/cvl